Emblem Corp is a Canada-based Company engaged in alternative medicine sector. The Company is producer and distributor of medical cannabis and cannabis derivatives licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR). The Company operates in one segment, the production and sale of medical cannabis to patients who have received medical authorizations to acquire and use cannabis. The Company offers fully integrated services covering the full cannabis spectrum, from growing to selling, as well as educating and also creating new forms of cannabinoid-based medication in standardized dosages. All of the Companyâ€™s assets are located in Canada.

Employees

Sector

Pharmaceuticals

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Toronto S.E. Other stock markets 19:59:45 18/03/2019 GMT			5-day change	1st Jan Change
1.880 ^CAD	+1.62%		+1.62%	+106.59%

14/05/19	Emblem Corp. Reports Earnings Results for the Full Year Ended December 31, 2018	CI
19/03/19	Emblem Corp.(TSXV:EMC) dropped from S&P/TSX Venture Composite Index	CI

Market Cap	248M 217M 201M 187M 353M 23.48B 361M 2.42B 933M 11.58B 933M 912M 40.21B	P/E 2017	-16.3x	P/E 2018	-4.48x
Enterprise Value	219M 192M 177M 166M 312M 20.73B 319M 2.13B 823M 10.23B 823M 805M 35.51B	EV / Sales 2017	72,352,077x	EV / Sales 2018	10,915,686x
Free-Float	98.36%	Yield 2017 *	-	Yield 2018	-

14/05/19	Emblem Corp. Reports Earnings Results for the Full Year Ended December 31, 2018	CI
19/03/19	Emblem Corp.(TSXV:EMC) dropped from S&P/TSX Venture Composite Index	CI
13/03/19	Aleafia Health Inc. completed the acquisition of Emblem Corp..	CI
06/03/19	Emblem Corp. Announces Amended By-Laws; Announces Change to the Registered Office	CI
19/12/18	Emblem Corp., Aleafia Health Inc. - M&A Call
18/12/18	Aleafia Health Inc. executed a letter of intent to acquire Emblem Corp. for approximately CAD 160 million.	CI
10/12/18	Emblem Corp Announces Executive Appointments	CI
20/11/18	Emblem Corp. Appoints Wayne Kreppner as Division President	CI
20/11/18	Emblem Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	CI
07/11/18	Emblem Corp. Announces Board Changes	CI
11/10/18	Emblem Bolsters Medical Division to Support Growth and Product Innovation with Appointment of Wayne Kreppner as President	CI
29/09/18	10330698 Canada Ltd. announced that it has received CAD 1 million in funding from Emblem Corp.	CI
23/09/18	DriveABLE Assessment Centres Inc. announced that it has received funding from Emblem Corp.	CI

Manager	Title	Age	Since
Tricia Symmes CEO	Chief Executive Officer	-	-
Nick Dean CEO	Chief Executive Officer	-	30/11/2017
Ethan Karayannopoulos IRC	Investor Relations Contact	-	-

Emblem Corp Share Price

Stocks

EMC

CA29082J1084

Pharmaceuticals

Valuation: Emblem Corp

Latest news : Emblem Corp

Press Releases: Emblem Corp

Quotes and Performance

Managers and Directors: Emblem Corp

Alternative Medicine

Financials

Company Profile

Director	Title	Age	Since
John H. Stewart BRD	Director/Board Member	-	-
Jeffrey Fineberg BRD	Director/Board Member	-	-
Terry Johnson BRD	Director/Board Member	-	05/12/2016

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EMBLEM CORP	+1.62%	+1.62%	-	-	0
YUNNAN BAIYAO GROUP CO.,LTD	+3.26%	+0.21%	-13.15%	-6.35%	12.33B
BEIJING TONGRENTANG CO., LTD	+5.18%	+0.21%	-35.64%	-57.79%	4.51B
DONG-E-E-JIAO CO., LTD.	+5.34%	+0.26%	-12.86%	-6.22%	4.11B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	+6.00%	+3.46%	+10.84%	-38.89%	3.6B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+6.96%	+0.34%	+13.92%	-15.00%	3.58B
HUBEI JUMPCAN PHARMACEUTICAL CO., LTD.	+3.90%	+1.85%	-8.91%	-7.63%	3.44B
TASLY PHARMACEUTICAL GROUP CO., LTD	+3.32%	-2.91%	-12.76%	-2.91%	2.91B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	+5.85%	-0.46%	-5.88%	-24.18%	2.23B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+2.79%	-1.04%	-12.25%	+25.46%	1.6B
Average	+4.42%	+0.22%	-8.52%	-14.83%	3.83B
Weighted average by Cap.	+4.51%	+0.13%	-10.12%	-15.82%

	2017	2018
Net sales	2.69 2.36 2.18 2.03 3.83 254.7 3.92 26.21 10.12 125.65 10.12 9.9 436.26	8.22 7.2 6.65 6.21 11.68 777.44 11.95 79.99 30.88 383.54 30.88 30.2 1.33K
Net income	-12.1M -10.6M -9.78M -9.13M -17.19M -1.14B -17.59M -118M -45.44M -564M -45.44M -44.45M -1.96B	-24.26M -21.24M -19.61M -18.31M -34.47M -2.29B -35.26M -236M -91.1M -1.13B -91.1M -89.1M -3.93B
Net Debt	-21.51M -18.84M -17.39M -16.24M -30.57M -2.03B -31.26M -209M -80.78M -1B -80.79M -79.01M -3.48B	-29.05M -25.44M -23.48M -21.93M -41.28M -2.75B -42.22M -283M -109M -1.36B -109M -107M -4.7B